275 related articles for article (PubMed ID: 26284586)
1. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
[TBL] [Abstract][Full Text] [Related]
2. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract][Full Text] [Related]
3. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
4. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
6. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
[TBL] [Abstract][Full Text] [Related]
7. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
8. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
[TBL] [Abstract][Full Text] [Related]
9. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
11. Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Endocrinol Invest; 2013 Dec; 36(11):1099-104. PubMed ID: 24084189
[TBL] [Abstract][Full Text] [Related]
12. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
[TBL] [Abstract][Full Text] [Related]
13. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
14. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
15. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D; Xing J; Trink B; Xing M
Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
[TBL] [Abstract][Full Text] [Related]
18. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
[TBL] [Abstract][Full Text] [Related]
19. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
20. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]